The role of thiopurine metabolite monitoring in inflammatory bowel disease

Expert Review of Gastroenterology and Hepatology

Volumn 8, Issue 4, 2014, Pages 383-392

  Beswick, Lauren ^a   Friedman, Antony B ^a   Sparrow, Miles P ^a  

^a MONASH UNIVERSITY   (Australia)

Author keywords

6 mercaptopurine; allopurinol; azathioprine; inflammatory bowel disease; metabolism; thiopurine methyl transferase; thiopurines

Indexed keywords

6 THIOGUANINE NUCLEOTIDE; ALLOPURINOL; AZATHIOPRINE; DRUG METABOLITE; MERCAPTOPURINE; MESALAZINE; METHYLMERCAPTOPURINE; PLACEBO; UNCLASSIFIED DRUG; ANTIMETABOLITE; METHYLTRANSFERASE; THIOPURINE METHYLTRANSFERASE;

ARTHRALGIA; BONE MARROW SUPPRESSION; BONE MARROW TOXICITY; CLINICAL PRACTICE; COLITIS; CONTROLLED CLINICAL TRIAL (TOPIC); CROHN DISEASE; DRUG ABSORPTION; DRUG CHOICE; DRUG DOSE ESCALATION; DRUG EFFICACY; DRUG METABOLISM; DRUG MONITORING; DRUG SAFETY; DRUG TOLERABILITY; FATIGUE; FEVER; FLU LIKE SYNDROME; GASTROINTESTINAL SYMPTOM; GENOTYPE PHENOTYPE CORRELATION; GOUT; HUMAN; INFLAMMATORY BOWEL DISEASE; LEUKOPENIA; LIVER TOXICITY; LOW DRUG DOSE; MYALGIA; OUTCOME ASSESSMENT; PANCREATITIS; PHARMACOGENOMICS; REVIEW; SIGNAL TRANSDUCTION; TREATMENT DURATION; ULCERATIVE COLITIS; INFLAMMATORY BOWEL DISEASES; METABOLISM; PROCEDURES;

6-MERCAPTOPURINE; ALLOPURINOL; ANTIMETABOLITES; AZATHIOPRINE; DRUG MONITORING; HUMANS; INFLAMMATORY BOWEL DISEASES; METHYLTRANSFERASES;

EID: 84898936829     PISSN: 17474124     EISSN: 17474132     Source Type: Journal    
DOI: 10.1586/17474124.2014.894878     Document Type: Review

References (63)

1. Ansari A, Arenas M, Greenfield SM, et al. Prospective evaluation of the pharmacogenetics of azathioprine in the treatment of inflammatory bowel disease. Aliment Pharmacol Ther 2008;28(8):973-83
2. Roblin X, Oussalah A, Chevaux JB, et al. Use of thiopurine testing in the management of inflammatory bowel diseases in clinical practice: a worldwide survey of experts. Inflamm Bowel Dis 2011;17(12): 2480-7
3. Peyrin-Biroulet L, Deltenre P, Ardizzone S, et al. Azathioprine and 6-mercaptopurine for the prevention of postoperative recurrence in Crohn's disease: a meta-analysis. Am J Gastroenterol 2009; 104(8):2089-96
4. Colombel JF, William J, Sandborn et al. Infliximab, azathioprine, or combination therapy for Crohn's disease. N Engl J Med 2010;362(15):1383-95
5. Le'mann M, Mary JY, Duclos B, et al. Infliximab plus azathioprine for steroid-dependent Crohn's disease patients: a randomized placebo-controlled trial. Gastroenterology 2006;130(4):1054-61
6. Panccione RGS, Middleton S, Marquez JR, et al. Infliximab, Azathioprine, or Infliximab & Azathioprine for treatment of moderate to severe ulcerative colitis: The UC success trial. Gastroenterology 2011;140(5):S134
7. Panés J, López-Sanromán A, Bermejo F, et al. Early azathioprine therapy is no more effective than placebo for newly diagnosed Crohn's disease. Gastroenterology 2013; 145(4):766-74; e1
8. Cosnes J, Bourrier A, Laharie D, et al. Early administration of azathioprine vs conventional management of Crohn's Disease: a randomized controlled trial. Gastroenterology 2013;145(4):758-65; e2; quiz e14-5
9. Chevaux JB, Peyrin-Biroulet L, Sparrow MP. Optimizing thiopurine therapy in inflammatory bowel disease. Inflamm Bowel Dis 2011;17(6):1428-35
10. Que'me'neur L, Gerland LM, Flacher M, et al. Differential control of cell cycle, proliferation, and survival of primary T lymphocytes by purine and pyrimidine nucleotides. J Immunol 2003;170(10): 4986-95
11. Tiede I, Fritz G, Strand S, et al. CD28-dependent Rac1 activation is the molecular target of azathioprine in primary human CD4+ T lymphocytes. J Clin Invest 2003;111(8):1133-45 (Pubitemid 36519931)
12. Dignass A, Van Assche G, Lindsay JO, et al. The second European evidence-based consensus on the diagnosis and management of Crohn's disease: current management. J Crohns Colitis 2010;4(1):28-62
13. Candy S, Wright J, Gerber M, et al. A controlled double blind study of azathioprine in the management of Crohn's disease. Gut 1995;37(5):674-8
14. Present DH, Korelitz BI, Wisch N, et al. Treatment of Crohn's disease with 6- mercaptopurine. A long-term, randomized, double-blind study. N Engl J Med 1980; 302(18):981-7 (Pubitemid 10125406)
15. Reinshagen M, Schu?tz E, Armstrong VW, et al. 6-thioguanine nucleotide-adapted azathioprine therapy does not lead to higher remission rates than standard therapy in chronic active crohn disease: results from a randomized, controlled, open trial. Clin Chem 2007;53(7):1306-14 (Pubitemid 47020987)
16. Dassopoulos T, Dubinsky MC, Bentsen JL, et al. Randomised clinical trial: individualised vs. weight-based dosing of azathioprine in Crohn's disease. Aliment Pharmacol Ther 2014;39(2):163-75
17. Gilissen LP, Wong DR, Engels LG, et al. Therapeutic drug monitoring of thiopurine metabolites in adult thiopurine tolerant IBD patients on maintenance therapy. J Crohns Colitis 2012;6(6):698-707
18. Dubinsky MC, Lamothe S, Yang HY, et al. Pharmacogenomics and metabolite measurement for 6-mercaptopurine therapy in inflammatory bowel disease. Gastroenterology 2000;118(4):705-13 (Pubitemid 30171620)
19. Gearry RB, Barclay ML. Azathioprine and 6-mercaptopurine pharmacogenetics and metabolite monitoring in inflammatory bowel disease. J Gastroenterol Hepatol 2005;20(8):1149-57 (Pubitemid 41602556)
20. Osterman MT, Kundu R, Lichtenstein GR, Lewis JD. Association of 6-thioguanine nucleotide levels and inflammatory bowel disease activity: a meta-analysis. Gastroenterology 2006;130(4):1047-53
21. Moreau ALS, Del Tedesco E, Rinaudo-Gaujous M, et al. Association between thiopurine metabolite levels and clinical remission in IBD patients: an updated meta-analysis. Gastroenterology 2013;144(5):S92
22. Gonza'lez-Lama Y, Bermejo F, Lo'pez-Sanroma'n A, et al. Thiopurine methyl-transferase activity and azathioprine metabolite concentrations do not predict clinical outcome in thiopurine-treated inflammatory bowel disease patients. Aliment Pharmacol Ther 2011;34(5):544-54
23. Haines ML, Ajlouni Y, Irving PM, et al. Clinical usefulness of therapeutic drug monitoring of thiopurines in patients with inadequately controlled inflammatory bowel disease. Inflamm Bowel Dis 2011;17(6): 1301-7
24. Kennedy NA, Asser TL, Mountifield RE, et al. Thiopurine metabolite measurement leads to changes in management of inflammatory bowel disease. Intern Med J 2013;43(3):278-86
25. Roblin X, Peyrin-Biroulet L, Phelip JM, et al. A 6-thioguanine nucleotide threshold level of 400 pmol/8 x 10(8) erythrocytes predicts azathioprine refractoriness in patients with inflammatory bowel disease and normal TPMT activity. Am J Gastroenterol 2008;103(12):3115-22
26. Lewis JD, Abramson O, Pascua M, et al. Timing of myelosuppression during thiopurine therapy for inflammatory bowel disease: implications for monitoring recommendations. Clin Gastroenterol Hepatol 2009;7(11):1195-201; quiz 1141-2
27. Schu?tz E, Gummert J, Mohr FW, et al. Should 6-thioguanine nucleotides be monitored in heart transplant recipients given azathioprine? Ther Drug Monit 1996; 18(3):228-33 (Pubitemid 26159572)
28. Bergan S, Bentdal O, Sødal G, et al. Patterns of azathioprine metabolites in neutrophils, lymphocytes, reticulocytes, and erythrocytes: relevance to toxicity and monitoring in recipients of renal allografts. Ther Drug Monit 1997;19(5):502-9 (Pubitemid 28116825)
29. Chrzanowska M, Kolecki P, Duczmal-Cichocka B, Fiet J. Metabolites of mercaptopurine in red blood cells: a relationship between 6-thioguanine nucleotides and 6-methylmercaptopurine metabolite concentrations in children with lymphoblastic leukemia. Eur J Pharm Sci 1999;8(4):329-34 (Pubitemid 29325025)
30. Hindorf U, Lindqvist M, Hildebrand H, et al. Adverse events leading to modification of therapy in a large cohort of patients with inflammatory bowel disease. Aliment Pharmacol Ther 2006;24(2):331-42 (Pubitemid 43972901)
31. Tandiari T, Eslick G, Leong R. Thiopurine metabolites measurement more effective in guiding ibd management when done during disease flare as supposed to during remission. J Crohn's Colitis 2013;7:S156
32. Angelberger S, Schaeffeler E, Teml A, et al. Mucosal improvement in patients with moderate to severe postoperative endoscopic recurrence of Crohn's disease and azathioprine metabolite levels. Inflamm Bowel Dis 2013;19(3):590-8
33. Colombel JF, Ferrari N, Debuysere H, et al. Genotypic analysis of thiopurine S-methyltransferase in patients with Crohn's disease and severe myelosuppression during azathioprine therapy. Gastroenterology 2000;118(6):1025-30 (Pubitemid 30346978)
34. Booth RA, Ansari MT, Loit E, et al. Assessment of thiopurine S-methyltransferase activity in patients prescribed thiopurines: a systematic review. Ann Intern Med 2011;154(12):814-23; W-295-8
35. Lichtenstein GR, Abreu MT, Cohen R, Tremaine W; American Gastroenterological Association. American Gastroenterological Association Institute medical position statement on corticosteroids, immunomodulators, and infliximab in inflammatory bowel disease. Gastroenterology 2006;130(3):935-9 (Pubitemid 43374542)
36. van Egmond R, Chin P, Zhang M, et al. High TPMT enzyme activity does not explain drug resistance due to preferential 6-methylmercaptopurine production in patients on thiopurine treatment. Aliment Pharmacol Ther 2012;35(10):1181-9
37. Chouchana L, Roche D, Narjoz C, et al. Screening of TPMT deficiency by phenotyping and genotyping: a retrospective study among 1500 IBD patients in France. Gastroenterology 2011;140(5):S281-2
38. Hindorf U, Appell ML. Genotyping should be considered the primary choice for pre-treatment evaluation of thiopurine methyltransferase function. J Crohns Colitis 2012;6(6):655-9
39. Lichtenstein GR, Hanauer SB, Sandborn WJ; Practice Parameters Committee of American College of Gastroenterology. Management of Crohn's disease in adults. Am J Gastroenterol 2009; 104(2):465-83; quiz 464, 484
40. Hindorf U, Lindqvist M, Peterson C, et al. Pharmacogenetics during standardised initiation of thiopurine treatment in inflammatory bowel disease. Gut 2006; 55(10):1423-31 (Pubitemid 44476786)
41. Pozler O, Chla'dek J, Malý J, et al. Steady-state of azathioprine during initiation treatment of pediatric inflammatory bowel disease. J Crohns Colitis 2010;4(6):623-8
42. Lowry PW, Franklin CL, Weaver AL, et al. Leucopenia resulting from a drug interaction between azathioprine or 6-mercaptopurine and mesalamine, sulphasalazine, or balsalazide. Gut 2001; 49(5):656-64 (Pubitemid 32989202)
43. de Graaf P, de Boer NK, Wong DR, et al. Influence of 5-aminosalicylic acid on 6-thioguanosine phosphate metabolite levels: a prospective study in patients under steady thiopurine therapy. Br J Pharmacol 2010; 160(5):1083-91
44. de Boer NK, Wong DR, Jharap B, et al. Dose-dependent influence of 5-aminosalicylates on thiopurine metabolism. Am J Gastroenterol 2007; 102(12):2747-53 (Pubitemid 350179331)
45. Hande S, Wilson-Rich N, Bousvaros A, et al. 5-aminosalicylate therapy is associated with higher 6-thioguanine levels in adults and children with inflammatory bowel disease in remission on 6-mercaptopurine or azathioprine. Inflamm Bowel Dis 2006; 12(4):251-7
46. Nguyen TM, Le Gall C, Lachaux A, Boulieu R. High thiopurine metabolite concentrations associated with lymphopenia in inflammatory bowel disease (IBD) pediatric patients receiving aminosalicylates combined with azathioprine. Int J Clin Pharmacol Ther 2010;48(4): 275-81
47. Terkeltaub R. Update on gout: new therapeutic strategies and options. Nat Rev Rheumatol 2010;6(1):30-8
48. Smith MA, Blaker P, Marinaki AM, et al. Optimising outcome on thiopurines in inflammatory bowel disease by co-prescription of allopurinol. J Crohns Colitis 2012;6(9):905-12
49. Chocair P, Duley J, Simmonds HA, et al. Low-dose allopurinol plus azathioprine/ cyclosporin/prednisolone, a novel immunosuppressive regimen. Lancet 1993; 342(8863):83-4 (Pubitemid 23192425)
50. Sparrow MP, Hande SA, Friedman S, et al. Allopurinol safely and effectively optimizes tioguanine metabolites in inflammatory bowel disease patients not responding to azathioprine and mercaptopurine. Aliment Pharmacol Ther 2005;22(5):441-6 (Pubitemid 41248111)
51. Sparrow MP, Hande SA, Friedman S, et al. Effect of allopurinol on clinical outcomes in inflammatory bowel disease nonresponders to azathioprine or 6-mercaptopurine. Clin Gastroenterol Hepatol 2007;5(2): 209-14 (Pubitemid 46216945)
52. Hoentjen F, Seinen ML, Hanauer SB, et al. Safety and effectiveness of long-term allopurinol-thiopurine maintenance treatment in inflammatory bowel disease. Inflamm Bowel Dis 2013;19(2):363-9
53. Dewit O, Starkel P, Roblin X. Thiopurine metabolism monitoring: implications in inflammatory bowel diseases. Eur J Clin Invest 2010;40(11):1037-47
54. Seinen ML, de Boer NK, Smid K, et al. Allopurinol enhances the activity of hypoxanthine-guanine phosphoribosyltransferase in inflammatory bowel disease patients during low-dose thiopurine therapy: preliminary data of an ongoing series. Nucleosides Nucleotides Nucleic Acids 2011;30(12):1085-90
55. Blaker PA, Arenas-Hernandez M, Smith MA, et al. Mechanism of allopurinol induced TPMT inhibition. Biochem Pharmacol 2013;86(4):539-47
56. Ansari A, Patel N, Sanderson J, et al. Low-dose azathioprine or mercaptopurine in combination with allopurinol can bypass many adverse drug reactions in patients with inflammatory bowel disease. Aliment Pharmacol Ther 2010;31(6):640-7
57. Lees CW, Maan AK, Hansoti B, et al. Tolerability and safety of mercaptopurine in azathioprine-intolerant patients with inflammatory bowel disease. Aliment Pharmacol Ther 2008;27(3):220-7
58. Beswick L, Hair CS, Dowling D. Letter: successful mercaptopurine therapy after azathioprine-related pancreatitis in patients with IBD. Aliment Pharmacol Ther 2013; 37(1):162
59. Ledder OD, Lemberg DA, Ooi CY, et al. Are thiopurines always contraindicated after thiopurine-induced pancreatitis in inflammatory bowel disease? J Pediatr Gastroenterol Nutr 2013;57(5):583-6
60. Hindorf U, Johansson M, Eriksson A, et al. Mercaptopurine treatment should be considered in azathioprine intolerant patients with inflammatory bowel disease. Aliment Pharmacol Ther 2009;29(6):654-61
61. Shih DQ, Nguyen M, Zheng L, et al. Split-dose administration of thiopurine drugs: a novel and effective strategy for managing preferential 6-MMP metabolism. Aliment Pharmacol Ther 2012;36(5):449-58
62. Musumba CO. Review article: the association between nodular regenerative hyperplasia, inflammatory bowel disease and thiopurine therapy. Aliment Pharmacol Ther 2013;38(9):1025-37
63. van Asseldonk DP, Jharap B, Kuik DJ, et al. Prolonged thioguanine therapy is well tolerated and safe in the treatment of ulcerative colitis. Dig Liver Dis 2011;43(2): 110-15